Edesa Biotech, INC 10-Q quarterly reports

Edesa Biotech's Q3 2026 Form 10-Q reveals a substantial increase in net loss and operating expenses, alongside persistent concerns regarding its ability to continue as a going concern.

Edesa Biotech reports a significant increase in R&D expenses for Q2 2026, driven by preparations for clinical trials, while net loss widens compared to the prior year period.

Edesa Biotech reported an increased net loss in Q1 2026 but ended the quarter with a stronger cash position, driven by recent equity raises and progress in its clinical programs for vitiligo and ARDS.

Edesa Biotech reports a net loss of $1.7 million, or $0.25 per common share, for Q3 2025, with a focus on advancing its vitiligo program.

Edesa Biotech reports a net loss of $3.2 million for the six months ended March 31, 2025, and provides an update on its clinical programs and recent financing activities.

Edesa Biotech reports a net loss of $1.6 million for the quarter ended December 31, 2024, and highlights recent financing activities to support ongoing clinical programs.

Edesa Biotech's Q3 2024 results show a reduced net loss compared to the previous year, alongside progress in clinical trials and government funding.

Edesa Biotech's Q2 2024 report shows a reduced net loss compared to the previous year, alongside updates on their clinical programs and financial activities.

Edesa Biotech reported a net loss of $1.7 million for the quarter ended December 31, 2023, while also highlighting progress in its clinical programs and securing new funding.